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ABSTRACT 
Objectives 
Patients with Fibromyalgia Syndrome (FM) often complain about a cluster of cognitive 
disorders that strongly interferes with their work and daily life, but the relationship between 
impaired cognitive functions and self-reported dysfunctions remains unclear. We aimed to 
investigate the presence of cognitive impairments in FM patients and to analyze the 
relationship between the impairments and their evaluation by the patients by means of a 
comparison with a group of healthy controls. 
Methods 
30 FM patients and 30 healthy controls performed a neuropsychological and clinical 
evaluation of short-term, long-term and working memory, executive functions, and self-
evaluation of cognitive impairment, depressive and anxiety symptoms. To thoroughly 
investigate the executive functions we adopted the model of Miyake and colleagues, which 
identifies four domains: shifting, inhibition, updating and access.  
Results and Conclusions 
Our results confirmed the presence of impairments of attention, long-term memory, working 
memory and shifting and updating executive functions in FM patients, compared to healthy 
controls.  
These impairments are reflected in subjective complaints independently of depressive symptoms. 
The use of a self-report questionnaire in clinical practice would provide a first and easy screen 
for the presence of cognitive impairment in FM patients and, in most cases, obviate the need 
for a time-consuming full neuropsychological test battery. 
 
KEY WORDS: cognitive impairments, Fibromyalgia, subjective complaints, 
neuropsychological tests.
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Significance and Innovation 
- Our study investigated the neuropsychological performance of fibromyalgia patients 
in short- and long-term memory, working memory and executive functions (EF), 
focusing on a multi-domains approach for EF. 
- Our results showed that, in Fibromyalgia patients, cognitive impairments are reflected 
in subjective complaints independently of depressive symptoms. 
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INTRODUCTION 
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread musculoskeletal pain 
associated with a heterogeneous series of other symptoms, including fatigue, stiffness, disrupted 
or non-restorative sleep and psychological distress, particularly mood depression [1,2].  
Patients with FM often complain about the so-called “Fibro-fog”, a cluster of cognitive 
disorders not always reflected in poor test-based performance, but which strongly interferes 
with work and daily life [3,4]. Bertolucci and colleagues reported that 50-80% of FM patients 
show a decline in working memory, attention and executive functions [5]. However, 
“executive functions” (EF) represent a multifaceted construct, composed of separable factors, 
which tap on different cognitive mechanisms and possibly involve the activity of different 
brain structures. Considering EF as a whole would therefore not allow identification of subtle 
differences in cognitive complaints. 
Although the presence of cognitive impairment has recently been added to the diagnostic 
criteria of the American College of Rheumatology (ACR) [1], cognitive dysfunctions remain 
one of the least assessed and treated FM domains in general clinical practice, also because of 
the expertise and time required for neuropsychological tests. One possible strategy to avoid 
these hindrances is to use self-report tools, which may, however, be biased by the 
concomitant presence of depressive symptoms [6]. Indeed, previous studies have found that 
depressive symptoms are the strongest single contributor to complaints of cognitive deficits in 
chronic pain patients [7,8].  
Some important questions regarding the exact nature of cognitive deficits and the relationship 
between impaired functions and self-reported dysfunction are therefore still unanswered. The 
present study aimed to address two issues: i) to analyze the neuropsychological performance 
of FM patients in short- and long-term memory, working memory and EF by means of a 
comparison with pain-free healthy controls; and ii) to investigate the relationship between 
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objective performance on standard neuropsychological tests and subjective self-perception of 
cognitive status in everyday life through a specific questionnaire, by means of explorative 
correlational analyses. 
To thoroughly investigate EF, we referred to the model elaborated by Miyake and colleagues 
[9] and revised by Fisk and Sharp [10], which identifies four correlated but partially separable 
main factors: shifting, which involves the ability to engage and disengage attention from 
different tasks; inhibition, which implies holding back automatic or preponderant responses; 
updating, the ability to monitor and code information and replace old non-relevant with new-
relevant information; and access, which mediates access to long-term memory representations 
and is involved in verbal fluency tasks.  
 
METHODS 
Subjects 
Thirty consecutive fibromyalgia patients (FM) attending the “Città della Salute e della Scienza” 
Hospital, University of Turin, were enrolled. Due to the high prevalence of FM in women and 
in order to avoid sex-related effects, only women were enrolled in the study. All patients had 
a diagnosis of FM made by an expert rheumatologist according to the criteria of the ACR [1]. 
Exclusion criteria were: under 18 or over 70 years old; low educational level (< 5 years’ education) 
or insufficient knowledge of the Italian language; history of medical condition associated with 
cognitive dysfunctions; neurological and/or severe psychiatric pathologies. 5 patients were 
not undergoing psychopharmacological treatments for FM, whereas 25 patients were taking 
antidepressants for the management of pain. As a control group, 30 healthy women (HC), 
balanced for age and educational level, were enrolled. In addition to the above exclusion 
criteria, HC were also to have no history of rheumatologic pathologies or chronic pain. The 
demographic characteristics of the two groups are given in Table 1. The mean (SD) level of 
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pain intensity of the sample was of 6.68 (2.59) on the Visual Analogue Scale (VAS), with an 
average disease severity of 63.48 (14.58), as assessed by the Fibromyalgia Impact 
Questionnaire (FIQ). FM patients scored an average of 9 (3.7) at the depression subscale of 
the Hospital Anxiety and Depression Scale, whereas controls of 5.4 (3.1). 
Procedure 
After giving written informed consent, all the subjects participated in a 90-minute testing 
session during which the clinical, neuropsychological and self-perception of cognitive 
dysfunction evaluations were performed.  
Disease severity due to FM was measured using the Fibromyalgia Impact Scale (FIQ) [11,12], 
while pain intensity experienced in the previous week was measured on a 0-10 Visual 
Analogue Scale (VAS). The presence of depressive and anxiety symptoms was evaluated 
through the Hospital Anxiety and Depression Scale (HADS).  
The neuropsychological assessment was made on EF, memory (Rey Auditory Verbal 
Learning Test) and working memory (N-Back task). In accordance with the Miyake model [9] 
later modified by Fisk and Sharp [10], and with reference to the article by Aboulafia-Brakha 
and colleagues [13], we used the Tower of London test for the inhibition, the Trail Making 
Test for the shifting, the Digit Span Test for the updating and the FAS test for the access EF 
domains.  
To assess self-evaluation of cognitive impairments, we used a self-report questionnaire 
originally developed to assess perceived changes in cognitive functioning in cancer patients: 
the Functional Assessment of Cancer Therapy - Cognition Scale (FACT-Cog 2) [14]. 
Although specifically constructed to evaluate the so-called “chemo-fog” in cancer patients 
[15,16], as the scale contained no references to oncological pathology or chemotherapy, it may 
be used with other populations [17,18]. The FACT-Cog was specifically constructed to 
minimize the impact of distress on patient reports by means of behaviorally-based items [14], 
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which are less susceptible to depressive and anxiety symptoms. For instance, the occurrence 
of subjective cognitive disturbances in the FACT-Cog is quantified by reference to behavioral 
frequencies (once a week), instead of standard system responses (somewhat), as the latter can 
be more prone to psychological bias. This is of particular importance in FM, which has been 
described as a stress-related disorder [19] with a high occurrence of psychological 
comorbidities [20].  
 
Materials 
Clinical description  
Fibromyalgia Impact Scale (FIQ) 
The questionnaire includes 20 items assessing the severity of the disease on a scale of 0-100, 
with a higher score corresponding to a higher level of impairment [11,12]. 
Hospital Anxiety and Depression Scale (HADS) 
The HADS consists of 14 items divided into two subscales: one for depression and one for anxiety. 
Each subscale score ranges from 0 to 21, with a score of 8 or more suggesting a clinically 
relevant level of depression/anxiety symptoms [21,22]. 
Neuropsychological evaluation 
Inhibition 
The Tower of London (ToL) task evaluates planning and inhibition EF [23]. The subject has 
to move three different colored disks from a prearranged sequence on three different pegs to 
match twelve predetermined goals. The task has to be done as quickly as possible, following 
several specific rules and in a given number of moves, a number that increases with the 
difficulty of the task. The execution time is registered as a dependent variable and then 
converted and compared with the normative data [24]. 
Shifting 
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The Trail Making Test (TMT) provides information on visual search, scanning, processing 
speed, mental flexibility and attention shifting [25,26]. It is composed of two parts: in the 
first, the subject has to connect numbers ascending from 1 to 25 (TMT-A); in the second, to 
alternate between numbers and letters (i.e., 1-A-2-B-3-C, etc.) (TMT-B). The test provides 
three scores: the times (in seconds) of parts A and B, and the difference between them (TMT-BA). 
Updating 
The Digit Span test (DS) assesses short-term verbal memory span and the ability to 
manipulate and update verbal information while in temporary storage [27,28]. Subjects are 
required to repeat, immediately following presentation, increasingly longer strings of single 
digit numbers, in either forward (DS-F) or reverse order (DS-B). For both trials, the final 
score is the number of digits correctly repeated. 
Access 
The F-A-S test assesses phonemic verbal fluency by requiring subjects to orally produce as many 
words as possible beginning with the letters F, A, or S within a time frame of 1 minute [29,30]. 
Memory 
The Rey Auditory Verbal Learning Test (RAVLT) [30,31] is a word-list learning task 
assessing short- and long-term memory. Subjects freely recall a 15-word list 5 times 
(immediate recall, RAVLT-I) after oral presentation. Fifteen minutes later, subjects are asked 
to recall again the 15-word list (delayed recall, RAVLT-D).  
Working memory 
Our N-Back paradigm was gathered from the work of Legrain and colleagues [32]. Subjects 
are presented with 3 blocks of 61 trials each. A cross remains at the center of the monitor for 
the entire duration of a block. Every 2400 ms two circles are presented, one on the left and 
one on the right of the central cross. The circles may be both blue or both yellow and remain 
on the screen for 600 ms. The subject has to match the color of the current visual target to the 
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color of the preceding one, judging whether the color is the same or not and pressing a certain 
key on the keyboard as quickly as possible (1-Back Task). The dependent variables are 
reaction time (RT) and type of response: correct, incorrect, omitted or anticipated (less than 
240 ms). 
Self-perception of cognitive dysfunction evaluation 
The FACT-Cog 2 [14] is a 50-item measure designed to assess cognitive complaints after 
chemotherapies in cancer patients. On a five-point Likert scale, subjects rate the frequency 
with which each statement had occurred in the previous week, with higher scores reflecting 
fewer cognitive problems and a better quality of life. The FACT-Cog yields seven subscale 
scores (Mental Acuity - MA, Concentration - Con, Verbal and Nonverbal Memory - Mem, 
Verbal Fluency - VF, Functional Interference - FI, Other People Noticed Deficits - OnD, and 
Impact on Quality of Life – QoL) and a Total (Tot) score.  
Statistical analyses 
The data were analyzed using the Statistical Package for Social Science - Version 20 (SPSS-20; 
SPSS Inc., Chicago, IL, USA). Independent sample t-tests were used to compare continuous 
variables between the FM and the HC groups. Pearson bivariate correlations were used to 
analyze the relationship between clinical, neuropsychological and metacognition variables in 
the FM group. To reduce Type 1 error, only the significantly different variables between the 
two groups were inserted into the correlational analyses. P-values lower than .05 were 
considered statistically significant. 
RESULTS 
Clinical description 
FM and controls differed significantly in the level of depressive and anxiety symptoms, with 
FM patients presenting higher scores on the HADS (Table 1). In particular, 22 FM patients 
(73.3%) vs. 10 (33.3%) HC presented a higher score than the cut-off on the HADS-D 
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subscale and 19 (63.3%) FM patients vs. 9 (30%) HC presented a higher score than the cut-
off in the anxiety subscale. Notably, even when HC showed above cut-off scores, this was 
close to it. 
Neuropsychological variables 
Detailed statistical values are given in Table 2. Groups means showed a significant difference 
between the two groups in the DS-B (updating/working memory), with the patients showing a 
worse performance compared to the HC, whereas only a trend towards a significant difference 
was found in the DS-F subtest (short-term memory). A significant difference was found in the 
RAVLT-D test (episodic memory), with the patients showing a lower number of words 
recalled compared to the HC. In addition, significant differences were found in the TMT-B 
test (attentional shifting), showing that the patients required more time than the controls to 
complete the task. 
Regarding the 1-Back, the results showed no difference in the accuracy between the two 
groups, but FM patients had longer reaction times than the controls (891 vs. 722 ms 
respectively). 
In order to bring out the individual differences that could be flattened by group analyses, we 
analyzed the individual scores by comparing, for each test, the number of subjects with a 
clinically deficient performance according to the age and education-corrected scores 
(equivalent score equal or minor to 1). The results showed that a significantly higher number 
of FM patients compared to the healthy controls had a deficient performance in both the 
subscale of the RAVLT test (episodic memory) and the ToL (problem solving/EF) (Figure 1).  
Self-perception of cognitive dysfunctions 
FM patients reported a significantly worse judgment compared to the control group in the 
total score and in all the subscales of the FACT-Cog (Table 3). Not only did patients declare 
deficits in all the cognitive abilities investigated, but also had lower scores in the “Other 
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People Noticed Deficits” (OnD) subscale, reporting that other people noticed their inadequate 
cognitive performance. In addition, FM patients reported lower scores on the QoL subscale, 
which evaluates the impact of cognitive performance on their quality of life.  
Correlations between clinical and neuropsychological variables in FM 
Given the exploratory nature of these analyses, we did not apply corrections for multiple 
comparisons [34].  
The severity of FM, as assessed by the FIQ, showed a statistically significant positive 
correlation with the TMT-B (r= 0.434, p=.021) and a trend toward a significant correlation 
with the TRc (r= 0.375, p= .05) (Table 4): the higher the severity of FM, the lower the ability 
to shift attention (TMT-B) and the higher the reaction times in the 1-Back task. No other 
significant correlations were found.  
Regarding the relationship between the FACT-Cog subscales and the clinical parameters 
(Table 4), the analyses showed statistically significant negative correlations between the FIQ 
and the Con (p=.008), the FI (p=.022), the QoL subscales (p=.002) and the Total score 
(p=.004): patients with more severe FM reported greater self-perception of cognitive 
impairments in concentration and attention, and complained of a greater negative impact of 
cognitive deficits on their quality of life. A significant correlation also emerged between the 
FIQ and the OnD subscales of the FACT-Cog (p=.012), and between the latter and pain 
intensity (p=.040). OnD measures how severe, in the patients’ opinion, their cognitive deficits 
are perceived by other people. Thus, greater severity of pain and clinical symptoms are 
positively correlated with patients’ perception that other people tend to notice  
the patients’ cognitive impairments. 
The correlational analyses between cognitive impairment perception and the psychological 
variables showed that the depression subscale of the HADS and the OnD subscale of the 
FACT-Cog were significantly and negatively correlated (r= -0.401, p=.028), suggesting that 
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patients with more severe depressive symptoms claim more that their cognitive deficits are 
noted by other people. 
Finally, the correlational analyses between the neuropsychological tests and the self-
perception of cognitive dysfunction showed statistically significant correlations between the 
VF subscale of the FACT-Cog and the DS-B (r= 0.396, p=.03), the TMT-B (r= -0.361,  
p=.049) and TMT-BA (r= -0.396, p=.03) scores, suggesting that a worse performance in these 
tests was correlated to higher complaints in the verbal fluency domain (EF) (Table 5).  
A significant correlation was also present between the QoL subscale of the FACT-Cog and 
the reaction times in the correct responses of the 1-Back task (r= -0.377, p=.04): patients with 
faster reaction times judged their quality of life as better (Table 5). 
 
DISCUSSION 
Fibromyalgia patients often complain about a cluster of cognitive disorders that strongly 
interferes with their work and daily life [3]. However, cognitive dysfunctions remain under-
recognized and under-treated. This because neuropsychological tests require 
neuropsychological expertise and are time consuming, and because the relationship between 
subjective cognitive complaints and objective neuropsychological tests in chronic pain 
patients is still controversial [6,7]. Recently, Landrø and colleagues [6] reopened this debate, 
finding that subjective complaints in chronic nonmalignant pain subjects were validated on 
objective neuropsychological assessment. Since Landrø’s study, as highlighted by McGuire 
[34], used norm-referenced neuropsychological tests and did not have a pain-free comparison 
group, we investigated the presence of cognitive impairment in FM patients and analyzed the 
relationship between the patients and their self-evaluation of cognitive impairment by means 
of a comparison with a group of healthy controls. 
Neuropsychological profile of FM patients 
Page 12 of 30
John Wiley & Sons, Inc.
Arthritis Care & Research
The finding that FM patients have poorer performances in working memory, attention and EF 
was reported by Bertolucci and colleagues [5]. However, EF represent a multifaceted 
construct, composed of separable factors, which tap on different cognitive mechanisms that 
possibly involve the activity of different brain structures. Considering EF as a whole would 
not allow identification of subtle differences in cognitive complaints. In the present study, we 
selected neuropsychological tests in order to cover the different EF aspects: inhibition, 
shifting, updating and access [9,10]. 
Our results indicated that FM patients were more impaired in long-term memory (delayed 
subscale of the Rey test), in the attention shifting (Trail Making Test-B) and in the updating 
component (Digit Span backward) of EF. In addition, although the accuracy of FM patients in 
visual working memory was comparable to that of the healthy controls, the former showed a 
significant slowdown in reaction times (1-Back task). 
Complaints about working memory functions are common across a wide variety of chronic 
pain states and, as reviewed by Berryman, moderate impairment in working memory can be 
consistently observed across studies and paradigms [35]. Consistently with previous studies 
showing a slowdown in FM patients’ response processing [36], our patients were slower in 
selecting whether the target was similar or different to a previous stimulus. Seo and 
colleagues also observed that when a greater amount of manipulation (e.g., 2-back condition) 
is required, FM patients also show reduced accuracy [36]. It is therefore possible that our task 
was sensitive enough to detect differences in reaction times, but not difficult enough to 
require a great amount of manipulation [37] to bring out differences in accuracy. 
Regarding the EF, patients showed impairments in the shifting subcomponent, as already 
highlighted by previous literature [38]. Poor performances on complex tests that involve 
interference or attention switching have also been found in other chronic pain states [39]. 
Notably, although the performance at the TMT-B is usually considered a measure of shifting 
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abilities [13], it also requires updating abilities. Therefore, it is possible that low 
performances at the TMT-B result from both shifting and updating deficits. In fact, the 
updating subcomponent, as measured by the DS-B, also appeared to be impaired. Although 
the patients’ mean score on the DS-B was slightly up on the normative data, FM patients 
showed a significantly lower performance compared to healthy controls. This result is in line 
with previous reports by Cherry and colleagues [40] and De Melo and colleagues [41] which 
showed that FM patients performed worse compared to patients with other chronic rheumatic 
diseases. In line with the literature, we did not observe deficits in the subcomponents of 
inhibition or access of EF. Veldhuijzen and colleagues [42], investigating the ability of FM 
patients to inhibit preponderant information, evidenced a slower performance than that of the 
controls, but equal accuracy. This finding parallels our results on the N-back task and may 
then point to an underlying problem of mental processing speed and/or psychomotor speed 
[42]. Evidence that FM patients are not impaired in the access domain is accumulating: FM 
patients did not show impairments in verbal fluency, either phonemic [43] or semantic [40]. 
In apparent contradiction, in a review of cognitive dysfunctions in FM [44], Glass and 
colleagues reported that several studies observed fluency disturbances in FM patients. 
Methodological problems or differences could account for contrasting results reported in the 
literature on cognitive deficits in FM. In fact, in some of the articles reviewed by Glass [44], 
the groups of FM and healthy controls were not balanced in sample size [45] or educational 
level [46]. Concerning the shifting function, other studies failed to show impairment in FM 
when comparing performances with the normative data [47,48]. 
The relationship between clinical and neuropsychological testing in FM patients 
Landrø found an accordance between the objective performance and the subjective 
complaints of cognitive impairments, suggesting that, in chronic pain patients, subjective 
complaints might reflect genuine cognitive deficits to a larger extent than previously thought [6]. 
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Consistently, Glass and colleagues reported a match between reported and objective deficits 
in memory capacity in FM patients [49]. 
Our results indicate a good correlation between the verbal fluency subscale of the FACT-Cog 
and executive functions and working memory tests, thus suggesting that FACT-Cog can be 
used as an effective screening tool for objective cognitive deficits. However, it should also be 
noted that not all the subscales showed strong correlations. Therefore, although subjective 
complaints can be used as an effective tool to identify objective deficits, a complete picture of 
patients’ cognitive status is better achieved with a more in-depth neuropsychological battery. 
Another caveat is that the lack of strong correlations can be explained by the operational 
definition of the tested constructs. What is considered as “memory” in everyday life is tested 
at a more fine-grained level in the neuropsychological domain. As such, the objective and 
subjective reports do not capture the same level of definition and, consequently, may not 
correlate completely. 
One possible confound in the interpretation of self-evaluation questionnaires is the 
concomitant presence of mood disturbances in the majority of chronic pain patients [50]. For 
instance, Williams and colleagues investigated the relationship between the self-perception of 
cognitive functioning and the other symptoms commonly present in FM (pain, fatigue, sleep 
and depressive and anxiety symptoms) [3]. They found that the domains of mood and fatigue 
were strongly associated with the perceived dyscognitions in FM, whereas pain was uniquely 
associated with perceived language deficits and, unexpectedly, was not related to attention or 
concentration. In agreement with this, the results of our study showed that the perceived 
cognitive dysfunctions were not associated with pain intensity. We found no association 
between the self-evaluation of cognitive functioning and depressive or anxiety symptoms. 
This is not surprising, as the FACT-Cog questionnaire is specifically constructed to minimize 
the impact of distress on patient reports [14]. It is possible that the presence of depressive 
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symptoms could be partially related to an increase in FM patients’ complaints, but that using 
the FACT-Cog could help to avoid this bias. 
The complaints of cognitive deficits were related to the severity of the disease as assessed by 
the FIQ. This result was expected, given that the FIQ evaluates the impact that FM symptoms 
have on patients’ daily life and that the presence of cognitive deficits is often reported as 
causing difficulties in everyday functioning. Not only complaints of cognitive deficits, but 
also objective deficits, and in particular a slowdown in reaction times and shifting deficits, 
demonstrated a relationship with the severity of the disease. No other relationship emerged 
between test performance and pain intensity, depressive and anxiety symptoms. With regard 
to both types of symptoms, data in the literature shows undefined results: a recent review 
reported that poor scores on EF measures do not seem related to mood disorders, but a 
correlation between verbal fluency and neuropsychiatric symptoms, such as hallucinations, 
irritability and anxiety, was described [5]. 
Limitations 
Our study presents some methodological limitations. First, the results of the correlational 
analyses should be interpreted with caution. Indeed, these results were obtained from a 
relatively small sample size and were not corrected for multiple comparisons given the 
exploratory nature of the analysis. Second, we did not select patients on the basis of their 
ongoing pharmacological therapy. Indeed, some medications can affect cognitive function, 
making it difficult to discern which cognitive deficit might be attributable to FM and which to 
medications. Nevertheless, most of our patients taking antidepressants for pain are treated with 
duloxetine, a dual antidepressant that does not significantly impair cognition [48]. In addition, 
this limitation does not invalidate the main result of the study, which concerns the degree of 
accordance between subjective and objective reports.  
Conclusion 
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To conclude, our data indicate that the long-term and working memory, shifting of attention 
and updating executive functions of FM patients are impaired compared to healthy controls. 
These impairments are reflected in subjective complaints independently of depressive 
symptoms. The use of a self-report questionnaire in clinical practice would provide a first and 
easy screen for the presence of cognitive impairment in FM patients and, in most cases, avoid 
the need for a time-consuming full neuropsychological test battery. 
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Table 1. Demographic and clinical characteristics of the FM and Control (HC) groups. 
Variable FM (30) HC (30) T (df) P value 
Age (Mean (SD)) 52.8 (9.6) 53.8 (12.4) -0.42 (58) .680 
Years of education (Mean (SD)) 10.9 (3.5) 12.4 (3.1) -1.77 (58) .081 
Marital status N° (%) N° (%)   
Single 3 (10%) 0 (0%)   
Cohabiting 1 (3.3%) 1 (3.3%)   
Married 22 (73.3%) 23 (76.7%)   
Divorced 4 (13.3%) 4 (13.3%)   
Widowed 0 (0%) 2 (6.7%)   
Work status N° (%) N° (%)   
Employed 18 (60%) 24 (80%)   
Unemployed 3 (10%) 1 (3.3%)   
Retired 3 (10%) 3 (10%)   
Housewife 6 (20%) 2 (6.7%)   
HADS Mean (SD) Mean (SD)   
HADS-Tot 18.2 (5.8) 11.2 (5.7) 4.7 (58) <.0001 
HADS-D  9.0 (3.7) 5.4 (3.1) 4.2 (58) <.0001 
HADS-A 9.2 (3.2) 5.5 (3.4) 4.3 (58) <.0001 
HADS: Hospital Anxiety and Depression Scale; HADS-Tot: total score of the Hospital 
Anxiety and Depression Scale; HADS-D: Hospital Anxiety and Depression Scale – 
Depression subscale; HADS-A: Hospital Anxiety and Depression Scale – Anxiety subscale. 
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 Table 2. Neuropsychological performance of FM patients (FM) and Healthy Controls 
(HC). Mean (SD) scores and t-test analyses are listed.  
  FP HC T (df) P value 
Verbal fluency/Access    
 FAS 37.7 (13.9) 42.1 (7.6) -1.54 (44.9) .131 
Short-term memory    
 DS-F 5.1 (1.0) 5.7 (1.2) -1.98 (58) .053 
Updating/working memory    
 DS-B 3.8 (1.1) 4.4 (0.9) -2.21 (58) .031 
Episodic memory    
 RAVLT-I 47.7 (11.6) 52.0 (7.5) -1.72 (49.7) .092 
 RAVLT-D 9.9 (3.6) 11.7 (2.4) -2.19 (50.4) .033 
Attentional shifting    
 TMT-A 42.4 (19.4) 35.8 (12.0) 1.60 (48.4) .117 
 TMT-B 97.3 (39.9) 75.7 (28.6) 2.40 (52.5) .020 
 TMT-BA 53.7 (29.9) 39.7 (21.5) 2.08 (52.6) .042 
Problem solving/Inhibition     
 ToL  26.9 (3.7) 27.5 (2.9) -0.57 (58) .567 
Working memory    
 1-Back     
 TRc 891.2 (185.0) 722.4 (131.9) 4.07 (58) <.0001 
 Ne 17.9 (20.6) 14.1 (7.9) 0.95 (37.51) .349 
 NV 3.8 (5.4) 4.6 (4.7) -0.61 (58) .543 
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FAS: Verbal Fluency Test; DS-F: Digit Span Forward; DS-B: Digit Span Backward; RAVLT-I: 
Rey Auditory Verbal Learning Test – immediate recall; RAVLT-D: Rey Auditory Verbal 
Learning Test – delayed recall; TMT-A: Trail Making Test A; TMT-B: Trail Making Test B; 
TMT-BA: Trail Making Test B minus A score; ToL: Tower of London Test;  
TRc: reaction time of correct responses; Ne: number of errors; NV: anticipations and omissions. 
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Figure 1. Percentage of FM patients (FM) and Healthy Controls (HC) with a clinically 
impaired performance (P.E= 0-1).  
FAS: Verbal Fluency Test; DS-F: Digit Span Forward; DS-B: Digit Span Backward; 
RAVLT-I: Rey Auditory Verbal Learning Test – immediate recall; RAVLT-D: Rey Auditory 
Verbal Learning Test – delayed recall; TMT-A: Trail Making Test A; TMT-B: Trail Making 
Test B; TMT-BA: Trail Making Test B minus A score; ToL: Tower of London Test. 
 
 
 
10% vs. 0%; p= N.S. 
40% vs. 20%; p= N.S. 
33.3% vs. 13.3%; p= N.S. 
13.3% vs. 0%; p=.038 
20% vs. 3%; p=.044 
10% vs. 0%; p= N.S. 
3.3% vs. 0%; p= N.S. 
3.3% vs. 0%; p= N.S. 
34.5% vs. 6.7%; p= .008 
RAVLT-I 
RAVLT-D 
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Table 3. Self-perception of cognitive dysfunctions (Fact-Cog). Mean (SD) and  
t-test analyses are listed.  
 
 
 
 
 
 
 
 
 
 
MA: Mental Acuity; Con: concentration; Mem: Verbal and Nonverbal Memory; 
VF: Verbal Fluency; FI: Functional Interference; OnD: Other People Noticed Deficits;  
QoL: Impact on Quality of Life; Tot: Total score.   
 FM HC T (df) P value 
MA 2.6 (0.8) 3.3 (0.7) -3.25 (58) .002 
Con 2.3 (0.8) 3.1 (0.7) -4.18 (58) <.0001 
Mem 2.4 (0.7) 3.1 (0.6) -3.79 (58) <.0001 
VF 2.2 (0.8) 2.9 (0.6) -3.97 (52.1) <.0001 
FI 2.4 (0.7) 3.2 (0.5) -5.89 (51.6) <.0001 
OnD 2.7 (1.0) 3.4 (0.4) -3.60 (39.3) .001 
QoL 2.1 (1.1) 3.5 (0.6) -5.93 (45.6) <.0001 
Tot 2.2 (0.6) 2.9 (0.4) -5.27 (52.9) <.0001 
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Table 4. Correlational analyses in FM patients. Pearson's correlation coefficients are 
listed.  
  FIQ VAS HADS-D HADS-A 
DS-B  -0.173 -0.150 -0.236 -0.065 
RAVLT-D  -0.169 -0.223 -0.189 -0.028 
TMT-B  0.434* 0.336 0.046 0.082 
TMT-BA  0.369 0.207 -0.038 0.055 
TRc  0.375* 0.244 0.139 0.181 
FACT-Cog MA -0.262 -0.162 -0.182 0.017 
 Con -0.493** -0.314 -0.272 -0.233 
 Mem 0.079 -0.144 -0.256 0.094 
 VF -0.355 -0.245 -0.35 -0.181 
 FI -0.430* -0.214 -0.296 -0.119 
 OnD -0.467* -0.390* -0.401* -0.24 
 QoL -0.568** -0.254 -0.245 -0.171 
 Tot -0.523** -0.325 -0.315 -0.162 
* p< .05; ** p< .01 
FIQ: Fibromyalgia Impact Scale; VAS: Visual Analogue Scale; HADS-D: Hospital Anxiety 
and Depression Scale – Depression subscale; HADS-A: Hospital Anxiety and Depression 
Scale – Anxiety subscale; DS-F: Digit Span Forward; DS-B: Digit Span Backward;  
RAVLT-D: Rey Auditory Verbal Learning Test – delayed recall; TMT-B: Trail Making Test 
B; TMT-BA: Trail Making Test B minus A score; TRc: reaction time of correct responses; 
MA: Mental Acuity; Con: concentration; Mem: Verbal and Nonverbal Memory; VF: Verbal 
Fluency; FI: Functional Interference; OnD: Other People Noticed Deficits; QoL: Impact on 
Quality of Life; Tot: Total score. 
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Table 5. Correlational analyses between the FACT-Cog and the neuropsychological tests 
in FM patients. Pearson's correlation coefficients are listed. 
 DS-B RAVLT-D TMT-B TMT-BA TRc 
MA 0.073 0.058 -0.153 -0.11 -0.1 
Con 0.163 0.071 -0215 -0.258 -0.124 
Mem 0.21 0.08 -0.122 -0.144 -0.006 
VF 0.396* -0.033 -0.361* -0.396* -0.116 
FI 0.143 0.119 -0.201 -0.196 -0.214 
OnD 0.313 0.023 -0.293 -0.266 0.081 
QoL 0.119 0.177 -0.307 -0.357 -0.377* 
Tot 0.137 0.13 -0.239 -0.28 -0.304 
*p <.05 
DS-B: Digit Span Backward; RAVLT-D: Rey Auditory Verbal Learning Test – delayed 
recall; TMT-B: Trail Making Test B; TMT-BA: Trail Making Test B minus A score;  
TRc: reaction time of correct responses; FACT-Cog subscales: MA: Mental Acuity;  
Con: concentration; Mem: Verbal and Nonverbal Memory; VF: Verbal Fluency;  
FI: Functional Interference; OnD: Other People Noticed Deficits; QoL: Impact on Quality of 
Life; Tot: Total score.  
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